FAQs

References: 1. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207-4213. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas. V.4.2020. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed August 26, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 3. Edeani A, Shirali A. Chapter 4: Tumor Lysis Syndrome. Onco-Nephrology Curriculum. American Society of Nephrology. 2016. https://www.asnonline.org/education/distancelearning/curricula/onco/Chapter4.pdf. Accessed August 26, 2020. 4. Cairo MS. Prevention and treatment of hyperuricemia in hematological malignancies. Clin Lymphoma. 2002;3(S1)S26-S31. 5. Venclexta [prescribing information]. East Windsor, NJ: Acrotech Biopharma LLC; 2020. 6. Sprycel [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2018. 7. Imbruvica [prescribing information]. Sunnyvale, CA: Pharmacyclics LLC; 2020. 8. Marqibo [prescribing information]. South San Francisco, CA: Talon Therapeutics; 2019. 9. Gazyva [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2020. 10. Blincyto [prescribing information]. Thousand Oaks, CA: Amgen Inc.; 2020. 11. Velcade [prescribing information]. Cambridge, MA: Millennium Pharmaceuticals, Inc; 2019. 12. Adriamycin [prescribing information]. Bedford, OH: Bedford Laboratories; 2013. 13. Kyprolis [prescribing information]. Thousand Oaks, CA: Onyx Pharmaceuticals, Inc.; 2020. 14. Revlimid [prescribing information]. Summit, NJ: Celgene Corporation; 2019. 15. Rituxan [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2020. 16. Bendeka [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2019. 17. Belay Y, Yirdaw K, Enawgaw B. Tumor lysis syndrome in patients with hematological malignancies. J Oncol. 2017. doi.org/10.1155/2017/9684909. 18. Bose P, Qubaiah O. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase. J Clin Pharm Ther. 2011;36(3):299-326. 19. Wilson FP, Berns JS. Onco-nephrology: tumor lysis syndrome. Clin J Am Soc Nephrol. 2012;7(10):1730-1739. 20. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. V.1.2021. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed September 28, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 21. ELITEK [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC. 22. Ueng S. Rasburicase (Elitek): a novel agent for tumor lysis syndrome. Proc (Bayl Univ Med Cent). 2005;18(3):275-279. 23. Goldman SC, Holcenberg JS, Finkelstein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97:2998-3003.